| abstract |
A prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group, and optionally a linker group. Prodrugs can be degraded by the enzyme thimet oligopeptide or TOP. Also disclosed are methods of designing prodrugs by using a TOP-degradable sequence in a conjugate, and methods of treating a patient with a prodrug of the present invention. |